A Phase 1b/2, Single-arm, Open-label, Multi-center Study of MP0250 in Combination With Osimertinib in Patients With EGFR-mutated Non-squamous Non-small Cell Lung Cancer (NSCLC) Pretreated With Osimertinib

Trial Profile

A Phase 1b/2, Single-arm, Open-label, Multi-center Study of MP0250 in Combination With Osimertinib in Patients With EGFR-mutated Non-squamous Non-small Cell Lung Cancer (NSCLC) Pretreated With Osimertinib

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Jul 2018

At a glance

  • Drugs MP 0250 (Primary) ; Osimertinib
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Molecular Partners AG
  • Most Recent Events

    • 15 Jun 2018 According to a Molecular Partners AG media release, data from this study will be presented at European Hematology Association (EHA)
    • 05 Apr 2018 According to a Molecular Partners AG media release, data from this study will be presented at the American Association of Cancer Research Annual Meeting 2018.
    • 09 Mar 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top